网站主页 > 化工产品目录 > 原料药 > 抗肿瘤药 > 替尼类抗肿瘤药

替尼类抗肿瘤药

替尼类抗肿瘤药物是一类新型生物靶向治疗肿瘤药物，目前在我国市场上常见的替尼类抗肿瘤药物包括：吉非替尼，伊马替尼，甲磺酸伊马替尼，尼罗替尼，舒尼替尼，拉帕替尼。
吉非替尼是由英国阿斯利康公司研制开发的一种特异性较高的抗肿瘤靶向治疗药物,是第一个用于治疗非小细胞肺癌的分子靶向药物，通过选择性地抑制表皮生长因子受体酪氨酸激酶(EGFR-TK)的信号传导通路而发挥作用。
伊马替尼是一种新型的2-苯胺嘧啶类酪氨酸激酶抑制剂。可以在细胞水平上有效抑制Bcr-abl酪氨酸激酶的活性，后者是慢性粒细胞性白血病 (CML) Ph染色体异常表达的产物，所以伊马替尼能选择性抑制Ber-abl阳性细胞系细胞及慢性粒细胞性白血病病人细胞的增殖和诱导其凋亡。
舒尼替尼为多靶点酪氨酸激酶抑制剂，包括血小板衍生生长因子受体、血管内皮生长因子受体和各种形式的突变激活干细胞因子受体，抑制肿瘤细胞RTKs表达失调和抗肿瘤血管生成。代谢依赖细胞色素P450酶。适用于胃肠间质瘤对伊马替尼耐药或者治疗后进展者，或用于肾细胞癌的治疗。

分享到：

点击具体产品，查看产品的最新价格，资讯，用途，供应信息

替尼类抗肿瘤药

资讯信息

替尼类抗肿瘤药

甲磺酸伊马替尼吉非替尼凡德他尼苹果酸舒尼替尼盐酸埃罗替尼来那替尼达沙替尼尼罗替尼伯舒替尼伊马替尼阿西替尼拉帕替尼埃罗替尼卡奈替尼卡纽替尼二盐酸盐达沙替尼塞卡替尼苏尼替尼Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-, (2S,3S)-2,3-dihydroxybutanedioate (1:1)N-[2-氯-4-[(6,7-二甲氧基-4-喹啉基)氧基]苯基]-N'-(5-甲基-3-异恶唑基)脲沃利替尼(S)-2-(4-CHLOROPHENYL)-1-(4-((5R,7R)-7-HYDROXY-5-METHYL-6,7-DIHYDRO-5H-CYCLOPENTA[D]PYRIMIDIN-4-YL)PIPERAZIN-1-YL)-3-(ISOPROPYLAMINO)PROPAN-1-ONE HYDROCHLORIDEAMDIZALISIBGlesatinibGUSACITINIB奥布替尼化合物 EDICOTINIB HCL化合物 MIFANERTINIB特泊替尼盐酸盐水合物尼洛替尼单盐二水化合物 DUVELISIB HYDRATE巴迪拉塞特4-Oxazolecarboxamide, N-[5-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-2-(2-methyl-4-pyridinyl)-, (2Z)-2-butenedioate (1:1)N-(2-氯-3-((5-氯-3-甲基-4-氧代-3,4-二氢喹唑啉-6-基)氨基)-4-氟苯基)-3-氟氮杂环丁烷-1-磺酰胺ILORASERTIBNelipepimut-SAMUVATINIB HYDROCHLORIDE (MP470 HYDROCHLORIDE)CYH33Trastuzumab Duocarmazine化合物 PALTIMATRECTINIBSulfuric acid, monododecyl ester, compd. with N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide (1:1)35-氯-N,N,74-三甲基-2,4-二氮杂-3(2,4)-嘧啶-7(1)-基-哌嗪-1(1),5(1,4)-二苯并庚烷-12-磺酰胺(2R,3R)-2,3-二羟基丁二酸盐阿卡替尼杂质化合物 AVUTOMETINIB POTASSIUM化合物 PIMICOTINIB呋喹替尼TAK-659CopanlisibMethoxyamine Hydrochloride化合物 E7090 SUCCINATEPARSACLISIB HYDROCHLORIDEOnvansertib fumarate化合物 ATM INHIBITOR-5ZETELETINIB HEMIADIPATENVL 520AMP945酒石酸盐E7050耐昔妥珠单抗EFT508 HCL可美替尼吡托布鲁替尼妥拉美替尼甲磺酸兰泽替尼一水合物4H-Thieno[2,3-c]pyrrol-4-one, 5,6-dihydro-6,6-dimethyl-2-[2-[(1-methyl-1H-pyrazol-5-yl)amino]-4-pyrimidinyl]-5-[2-(4-morpholinyl)ethyl]-, methanesulfonate (1:1)4-Pyridinecarboxamide, N-[7-chloro-1-[(3R)-1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]hexahydro-1H-azepin-3-yl]-1H-benzimidazol-2-yl]-2-methyl-, methanesulfonate, hydrate (1:1:3)Pyrido[3,4-b]pyrazin-5-amine, 7-[4-[1-(methylsulfonyl)-4-piperidinyl]phenyl]-N-[(2S)-2-morpholinylmethyl]-, acetate (1:1)4-Oxazolecarboxamide, N-[5-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-2-(2-methyl-4-pyridinyl)-, methanesulfonate (1:1)SEVABERTINIB化合物 BTK-IN-30托西尼布磷酸盐AC-220;AC2201-[[[4-[(4-氟-2-甲基-1H-吲哚-5-基)氧基]-6-甲氧基-7-喹啉基]氧基]甲基]环丙胺化合物 OLMUTINIB HYDROCHLORIDEARQ-531维卡布鲁替尼DS-6051B化合物HM43239化合物 ZURLETRECTINIB宗格替尼Benzamide, 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-, (2Z)-2-butenedioate (1:1)1334302-63-4PegdinetanibGILTERITINIB FUMARATE(S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amineE-7090化合物 DERAZANTINIB DIHYDROCHLORIDEATR INHIBITOR 1Vecabrutinib succinateEGFR-IN-761,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N′-[4-[[7-methoxy-6-[(methylamino)carbonyl]-4-quinolinyl]oxy]phenyl]-, (2E)-2-butenedioate (2:1)1(2H)-Isoquinolinone, 2-[3-[2-amino-6-[1,2,3,6-tetrahydro-1-(3-oxetanyl)-4-pyridinyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2-(hydroxymethyl)phenyl]-6-cyclopropyl-8-fluoro-, methanesulfonate (1:2)4-QuinazolinaMine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-Methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, (2E)-2-butenedioate (1:2)化合物 DILMAPIMOD TOSYLATE齐帕勒替尼化合物 MIRANSERTIB MESYLATE伏拉塞替三盐酸盐BDTX-189ZETELETINIB化合物 EDRALBRUTINIBAS17634-Oxazolecarboxamide, N-[5-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-2-(2-methyl-4-pyridinyl)-, 4-methylbenzenesulfonate (1:1)Sulfuric acid, monododecyl ester, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N′-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)LY2228820CP-868596XL 647 对甲苯磺酸盐伊他替尼1080645-95-9CG-806莫博替尼TPX-0046BLU-451(LNG451)4-Oxazolecarboxamide, N-[5-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-2-(2-methyl-4-pyridinyl)-, phosphate (1:1)Sulfuric acid, monododecyl ester, compd. with 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide (1:1)FGFR3 inhibitor LOXO-435 (LY3866288)1H-Pyrazole-1-acetamide, N-[(2,6-difluorophenyl)methyl]-3-(6-methyl-2-pyridinyl)-4-(4-quinolinyl)-INCB0400934-Oxazolecarboxamide, N-[5-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-2-(2-methyl-4-pyridinyl)-阿美替尼甲磺酸盐3H-Pyrrolo[3,4-c]pyridin-3-one, 6-[[(1R,2S)-2-aminocyclohexyl]amino]-7-fluoro-1,2-dihydro-4-(1-methyl-1H-pyrazol-4-yl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)Hexanedioic acid, compd. with (6R)-7-[(3,4-difluorophenyl)methyl]-6,7-dihydro-6-(methoxymethyl)-2-[5-methyl-2-[(1-methyl-1H-pyrazol-5-yl)amino]-4-pyrimidinyl]imidazo[1,2-a]pyrazin-8(5H)-one (1:2)4-((二甲氨基)甲基)-3-(2-氟-3-((N-甲基氨磺酰基)氨基)苄基)-2-氧代-2H-色烯-7-基二甲基氨基甲酸酯3-三氟甲基-4-[(4-甲基哌嗪-1-基)甲基]苯胺VARLITINIB TOSYLATECS-2696化合物 ALISERTIB SODIUM HYDRATE化合物 TOZASERTIB LACTATECSF1R-IN-2MG-516 malate1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE, 1-(1,1-DIMETHYLETHYL)-N-[(5R)-2,3,4,5-TETRAHYDRO-8-[2-[(1-METHYL-1H-PYRAZOL-4-YL)AMINO]-4-PYRIMIDINYL]-2-(3-OXETANYL)-1H-2-BENZ二对甲苯磺酸拉帕替尼木利替尼坦度替尼替尼达普多韦替尼伊马替尼合成中间体Ⅰ来他替尼N-去甲基伊马替尼奥替尼啶,奥克太啶替尼索洛尔替拉替尼巴氟替尼替尼西坦伊马替尼杂质A伊马替尼杂质B卡奈替尼替尼酸吡替尼定它赛瓦(埃罗替尼)伊马替尼杂质E阿法替尼伊马替尼杂质F莫立替尼伊玛替尼胺盐酸埃诺替尼伊马替尼杂质C替尼酮拉帕替尼中间体甲苯磺酸索拉替尼替尼达普钠拉帕替尼碱依马替尼甲磺酸盐伊马替尼杂质D埃罗替尼中间体舒尼替尼中间体3埃罗替尼中间体埃萝替尼卡那替尼甲磺酸苏尼替尼替尼拉平伊马替尼进口标准杂质B尼罗替尼溴替尼持舒尼替尼中间体安替尼特替尼沙秦伊马替尼进口标准杂质C

替尼类抗肿瘤药

资讯信息

替尼类抗肿瘤药

最新供应信息